Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

•Addition of ramucirumab to docetaxel in NSCLC post-platinum setting led to an improvement of overall survival in the REVEL study.•This analysis examined quality of life as assessed by the Lung Cancer Symptom Scale (LCSS) and clinician-reported functional status.•Time to deterioration for all LCSS scores and time to PS ≥2 were similar in both arms.•Adding ramucirumab to docetaxel in NSCLC post-platinum setting did not impair patient quality of life, symptoms or functioning.